(Q35607718)

9 August 2017

title

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers (English)

1 reference

9 August 2017

1 reference

Kelly E Dooley

1

1 reference

9 August 2017

Radojka M Savic

2

1 reference

9 August 2017

Jeong-Gun Park

3

1 reference

9 August 2017

Yoninah Cramer

4

1 reference

9 August 2017

Richard Hafner

5

1 reference

9 August 2017

Evelyn Hogg

6

1 reference

9 August 2017

Jennifer Janik

7

1 reference

9 August 2017

Mark A Marzinke

8

1 reference

9 August 2017

Kristine Patterson

9

1 reference

9 August 2017

Constance A Benson

10

1 reference

9 August 2017

Laura Hovind

11

1 reference

9 August 2017

Susan E Dorman

12

1 reference

9 August 2017

David W Haas

13

1 reference

9 August 2017

ACTG A5311 Study Team

14

1 reference

9 August 2017

language of work or name

English

0 references

publication date

30 March 2015

1 reference

Antimicrobial Agents and Chemotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

59

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

3399-3405

1 reference

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Cost-effectiveness of novel first-line treatment regimens for tuberculosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Three months of rifapentine and isoniazid for latent tuberculosis infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Adverse Effects of Rifampin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432148

High-dose rifampicin: how do we proceed?

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25824215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.05128-14

1 reference

9 August 2017

1 reference

9 August 2017

1 reference